

Amanda C Guidon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7584774/publications.pdf>

Version: 2024-02-01

45
papers

1,496
citations

623574

14
h-index

345118

36
g-index

45
all docs

45
docs citations

45
times ranked

1981
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and neuromuscular disorders. <i>Neurology</i> , 2020, 94, 959-969.	1.5	233
2	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	2.8	137
3	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	15.2	133
4	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. <i>JAMA Neurology</i> , 2020, 77, 582.	4.5	126
5	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116803.	0.3	110
6	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <i>Neurology</i> , 2019, 93, e1093-e1103.	1.5	107
7	<sc>COVID</sc>â€19 in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2020, 62, 254-258.	1.0	97
8	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
9	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , The, 2020, 19, 970-971.	4.9	85
10	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <i>Oncologist</i> , 2019, 24, 435-443.	1.9	80
11	Neuromuscular Disorders in Pregnancy. <i>Neurologic Clinics</i> , 2012, 30, 889-911.	0.8	32
12	A Retrospective study of complications of therapeutic plasma exchange in myasthenia. <i>Muscle and Nerve</i> , 2013, 47, 170-176.	1.0	30
13	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	1.0	24
14	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
15	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 299-302.	2.1	19
16	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
17	Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (<sc>MGâ€CE</sc>). <i>Muscle and Nerve</i> , 2021, 64, 270-276.	1.0	16
18	Neuromuscular Disorders in Pregnancy. <i>Seminars in Neurology</i> , 2017, 37, 643-652.	0.5	12

#	ARTICLE	IF	CITATIONS
19	Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1785-1806.	0.4	12
20	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
21	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021, 1, Itab014.	1.2	10
22	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. <i>Journal of Clinical Oncology</i> , 2018, 36, 127-127.	0.8	10
23	Case 22-2019: A 65-Year-Old Woman with Weakness, Dark Urine, and Dysphagia. <i>New England Journal of Medicine</i> , 2019, 381, 275-283.	13.9	9
24	Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 7-9.	1.0	9
25	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
26	Efgartigimod. <i>Neurology</i> , 2019, 92, 1079-1080.	1.5	8
27	Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. <i>Muscle and Nerve</i> , 2021, 64, 651-656.	1.0	7
28	Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms. <i>Oncologist</i> , 2022, 27, e402-e405.	1.9	7
29	Peripheral Neuropathies in Pregnancy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 100-114.	0.4	6
30	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.4	6
31	Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapy. <i>Muscle and Nerve</i> , 2021, 63, E21-E24.	1.0	4
32	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3060-3060.	0.8	4
33	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3096-3096.	0.8	4
34	Neuromuscular ultrasound findings in eosinophilic fasciitis: A case series and literature review. <i>Muscle and Nerve</i> , 2018, 58, E15-E18.	1.0	3
35	On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness. <i>Muscle and Nerve</i> , 2018, 58, 743-744.	1.0	3
36	The neuromuscular fellowship portal and match. <i>Muscle and Nerve</i> , 2022, 65, 640-645.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Consensus disease definitions for the spectrum of neurologic immune related adverse events.. Journal of Clinical Oncology, 2021, 39, 2647-2647.	0.8	2
38	Comment: A growing role for nerve ultrasound in diagnosis and management of CIDP?. Neurology, 2015, 84, 808-808.	1.5	1
39	Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravis. Muscle and Nerve, 2019, 60, E35-E37.	1.0	1
40	Comment on <sc>COVID</sc>-19 in patients with myasthenia gravis: Author response. Muscle and Nerve, 2020, 62, E87-E88.	1.0	1
41	Reply to "Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities", Annals of Neurology, 2020, 88, 200-201.	2.8	1
42	Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty Chewing. New England Journal of Medicine, 2019, 380, 1566-1574.	13.9	0
43	Diagnostic testing for ocular myasthenia gravis. Neurology, 2020, 95, 563-564.	1.5	0
44	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
45	Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle and Nerve, 0, , .	1.0	0